COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry

Shane Hanon,Guy Brusselle,Maud Deschampheleire,Renaud Louis,Alain Michils,Rudi Peché,Charles Pilette,Peter Rummens,Daniel Schuermans,Hélène Simonis,Olivier Vandenplas,Florence Schleich
DOI: https://doi.org/10.1183/13993003.02857-2020
IF: 24.3
2020-10-22
European Respiratory Journal
Abstract:Epidemiological studies suggest that patients with asthma are not at an increased risk of severe coronavirus disease 2019 (COVID-19) caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1–3]. Recent studies indicate that the severity of COVID-19 in patients with asthma is likely to depend on multiple factors. A type 2-low asthma phenotype, use of oral corticosteroids and severe asthma could be aggravating factors, while maintenance treatment with inhaled corticosteroids (ICS) and good asthma control are probably protective [4]. However, there is currently scarce information on the risk associated with COVID-19 in subjects with severe asthma and/or the use of biologics. Since eosinopenia is a biomarker for the severity of COVID-19 [5], the eosinophil depletion induced by anti-IL5 and anti-IL5 receptor blocking monoclonal antibodies raises concern in patients and their treating physicians.
respiratory system
What problem does this paper attempt to address?